Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO Sarcoma and Rare Cancers 2023 | Investigating the efficacy of perSARC to predict STS recurrence and OS

Michiel Van De Sande, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, discusses the clinical efficacy of the perSARC model to determine the risk of developing local recurrence or distant metastasis in patients with soft tissue sarcoma (STS). This online tool proposes to predict such events based on patient characteristics, and is primarily used the relative effectiveness of radiotherapy and surgery in the treatment of soft tissue sarcoma. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.